8V3A image
Entry Detail
PDB ID:
8V3A
Title:
Crystal structure of KRAS-G12C (GDP-bound) in complex with BBO-8520
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-11-27
Release Date:
2024-12-18
Method Details:
Experimental Method:
Resolution:
1.67 Å
R-Value Free:
0.18
R-Value Work:
0.15
R-Value Observed:
0.15
Space Group:
I 2 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:GTPase KRas
Mutations:G12C C118S
Chain IDs:A, B
Chain Length:170
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation

Abstact

Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. This approach provides no direct target coverage of the active protein. Expectedly, adaptive resistance to KRASG12C (OFF)-only inhibitors is observed in association with increased expression and activity of KRASG12C(ON). To provide optimal KRASG12C target coverage, we have developed BBO-8520, a first-in-class, direct dual inhibitor of KRASG12C(ON) and (OFF) forms. BBO-8520 binds in the Switch-II/Helix3 pocket, covalently modifies the target cysteine and disables effector binding to KRASG12C(ON). BBO-8520 exhibits potent signaling inhibition in growth factor activated states where current (OFF)-only inhibitors demonstrate little measurable activity. In vivo, BBO-8520 demonstrates rapid target engagement and inhibition of signaling, resulting in durable tumor regression in multiple models, including those resistant to KRASG12C(OFF)-only inhibitors. BBO-8520 is in Phase 1 clinical trials in patients with KRASG12C non-small cell lung cancer (NSCLC).

Legend

Protein

Chemical

Disease

Primary Citation of related structures